Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.

被引：0
|
作者：
Tang, Lichen
He, Min
Wu, Jiong
Wang, Zhonghua
Liu, Guangyu
Yu, Keda
Geng, Cuizhi
Fan, Zhimin
Ling, Rui
Qiao, Guangdong
Cai, Li
Luo, Ting
Jin, Feng
Wang, Haibo
Zhang, Anqin
Zhang, Hongwei
Zeng, Xiaohua
Wang, Xiaojia
Jiang, Ming
Shao Zhimin
机构：
[1] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
[3] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Dept Oncol, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China
[5] Fourth Hosp Hebei Med Univ, Shijiazhuang, Peoples R China
[6] First Hosp Jilin Univ, Dept Breast Surg, Changchun, Peoples R China
[7] Air Force Mil Med Univ, Xijing Hosp, Xian, Peoples R China
[8] Yuhuangding Hosp Yantai, Yantai, Peoples R China
[9] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[10] Sichuan Univ, Breast Dis Ctr, West China Hosp, Chengdu, Peoples R China
[11] First Hosp China Med Univ, Dept Breast Surg, Shenyang, Peoples R China
[12] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
[13] Guangdong Women & Children Hosp, Guangzhou, Peoples R China
[14] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[15] Chongqing Univ, Dept Breast Canc Ctr, Canc Hosp, Chongqing, Peoples R China
[16] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Canc & Basic Med, Chinese Acad Sci,Dept Med Oncol,Canc Hosp, Hangzhou, Peoples R China
[17] Cent Hosp Wuhan, Wuhan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
550
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHARMACOECONOMIC ANALYSIS OF PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS DOXORUBICIN IN PATIENTS WITH METASTATIC BREAST CANCER AT HIGH RISK OF CARDIAC EVENTS
    Krysanov, I
    Tiapkina, M.
    VALUE IN HEALTH, 2016, 19 (07) : A731 - A732
  • [22] CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
    Oaknin, Ana
    Barretina, Pilar
    Perez, Xavier
    Jimenez, Laura
    Velasco, Montserrat
    Alsina, Maria
    Brunet, Joan
    Ramon Germa, Josep
    Beltran, Miguel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (01) : 87 - 91
  • [23] Implications of BRCA mutations on recurrent ovarian cancer outcome treated with pegylated liposomal doxorubicin (PLD)
    Safra, Tamar
    Borgato, Lucia
    Nicoletto, Maria Ornella
    Donach, Martin Edward
    Rolnitzky, Linda
    Geva, Ravit
    Peles, Sharon
    Pua, Thara
    Novetsky, Akiva
    Gabizon, Alberto
    Muggia, Franco
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [24] Pegylated liposomal doxorubicin (PLD) and weekly paclitaxel as first line therapy in metastatic breast cancer
    Fulfaro, F.
    Valerio, M. R.
    Cicero, G.
    Rinaldi, G.
    Intrivici, C.
    Pizzo, T.
    Crosta, A.
    Scibilia, C.
    Gebbia, N.
    ANNALS OF ONCOLOGY, 2006, 17 : XI10 - XI11
  • [25] Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in patients with intermediate sensitive relapsing advanced ovarian cancer
    Stuart, G.
    Oza, A.
    Provencher, D.
    Bentley, J.
    Plante, M.
    Lotocki, R.
    Power, P.
    Miller, D.
    Ghatage, P.
    Pouliot, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 272 - 272
  • [26] PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND GEMCITABINE (G) COMBINATION IN METASTATIC BREAST CANCER (MBC) PATIENTS: ACTIVITY AND TOXICITY
    Fabi, A.
    Papaldo, P.
    Ciccarese, M.
    Salesi, N.
    Lorusso, V.
    Ferretti, G.
    Di Cocco, B.
    Carlini, P.
    Cecere, F.
    Pellicciotta, M.
    Morace, N.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2004, 15 : 24 - 24
  • [27] Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (CaelyxA®)
    Boers-Sonderen, Marye J.
    van Herpen, Carla M. L.
    van der Graaf, Winette T. A.
    Desar, Ingrid M. E.
    Arens-van der Logt, Mirjam G. W.
    de Beer, Yvo M.
    Ottevanger, Petronella B.
    van Erp, Nielka P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 457 - 463
  • [28] Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)
    Marye J. Boers-Sonderen
    Carla M. L. van Herpen
    Winette T. A. van der Graaf
    Ingrid M. E. Desar
    Mirjam G. W. Arens- van der Logt
    Yvo M. de Beer
    Petronella B. Ottevanger
    Nielka P. van Erp
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 457 - 463
  • [29] Cardiac safety of pegylated liposomal doxorubicin (PLD) in combination with trastuzumab (T) in patients with metastatic breast cancer (MBC): Results from a multicenter phase II study
    Stickeler, E.
    Watermann, D. O.
    Woll, J.
    Foeldi, M.
    Gitsch, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
    Jones, Robin L.
    Herzog, Thomas J.
    Patel, Shreyaskumar R.
    von Mehren, Margaret
    Schuetze, Scott M.
    Van Tine, Brian A.
    Coleman, Robert L.
    Knoblauch, Roland
    Triantos, Spyros
    Hu, Peter
    Shalaby, Waleed
    McGowan, Tracy
    Monk, Bradley J.
    Demetri, George D.
    CANCER MEDICINE, 2021, 10 (11): : 3565 - 3574
12345